肺部疾病是全球范圍內(nèi)威脅人類(lèi)健康的主要疾病之一，肺部疾病的臨床治療藥物包括止咳祛痰藥、支氣管擴(kuò)張劑、抗纖維化藥物、糖皮質(zhì)激素、化療藥物、靶向藥物、生物制劑等。羥基紅花黃色素A可通過(guò)減輕炎癥反應(yīng)、減輕氣道高反應(yīng)性、減輕氧化應(yīng)激反應(yīng)、阻止肺纖維化、抗肺癌對(duì)多種肺部疾病發(fā)揮治療作用?？偨Y(jié)了羥基紅花黃色素A防治肺部疾病的藥理作用研究進(jìn)展，為羥基紅花黃色素A的臨床應(yīng)用提供參考。

Pulmonary diseases are one of the major threats to human health worldwide. Clinical treatment drugs for pulmonary diseases include cough suppressants, bronchodilators, anti-fibrotic drugs, glucocorticoids, chemotherapy drugs, targeted drugs, biologics, etc. Hydroxysafflor yellow A can exert therapeutic effects on various pulmonary diseases by reducing inflammation response, airway hyperresponsiveness, oxidative stress response, preventing pulmonary fibrosis, and anti-lung cancer. This article summarizes the pharmacological research progress of hydroxysafflor yellow A in preventing and treating pulmonary diseases, providing reference for the clinical application of hydroxysafflor yellow A.

R285.5;R974

攀枝花市指導(dǎo)性科技計(jì)劃（2024ZD-S-122）